REP 2055

Drug Profile

REP 2055

Alternative Names: REP 9AC

Latest Information Update: 06 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator REPLICor; University of Adelaide
  • Class Antivirals; Nucleic acids; Oligonucleotides; Polymers
  • Mechanism of Action Hepatitis B virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Hepatitis B

Most Recent Events

  • 06 Jul 2017 Active development is ongoing in Bangladesh and Canada
  • 04 Apr 2017 No recent reports of development identified - Phase-I/II for Hepatitis B in Bangladesh (IV)
  • 04 Apr 2017 No recent reports of development identified - Preclinical for Hepatitis B in Canada (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top